The Role of Procalcitonin in Respiratory Infections

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2012 Mar 3

PMID 22382693

Authors

Laura Certain

Philipp Schuetz

Affiliations

Soon will be listed here.

Abstract

Accurate diagnosis, risk stratification, and decisions about the need for and optimal duration of antibiotic therapy are cornerstones of the management of patients with respiratory infections. A growing body of evidence supports the use of procalcitonin, a marker of bacterial infection, in addition to conventional clinical parameters to improve diagnostic and prognostic assessment in patients with suspicion of respiratory infections. In addition, several randomized controlled trials indicate that procalcitonin may be used for clinical decision making about initiation and optimal duration of antibiotic therapy. For patients with respiratory infections, procalcitonin-guided antibiotic therapy resulted in less antibiotic use without any apparent adverse patient outcome. For other infections outcome studies are currently lacking. This review summarizes the results of recent investigations of procalcitonin in respiratory infections to provide physicians an overview of the utility and limitations of procalcitonin when used for bedside decision making.

References

Duflo F, Debon R, Monneret G, Bienvenu J, Chassard D, Allaouchiche B . Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology. 2001; 96(1):74-9. DOI: 10.1097/00000542-200201000-00018. View

Hatzistilianou M . Diagnostic and prognostic role of procalcitonin in infections. ScientificWorldJournal. 2010; 10:1941-6. PMC: 5763968. DOI: 10.1100/tsw.2010.181. View

Don M, Valent F, Korppi M, Falleti E, De Candia A, Fasoli L . Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood. Scand J Infect Dis. 2007; 39(2):129-37. DOI: 10.1080/00365540600951283. View

Ugajin M, Miwa S, Shirai M, Ohba H, Eifuku T, Nakamura H . Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J. 2010; 37(2):371-5. DOI: 10.1183/09031936.00011910. View

Hillas G, Vassilakopoulos T, Plantza P, Rasidakis A, Bakakos P . C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J. 2009; 35(4):805-11. DOI: 10.1183/09031936.00051309. View

Tang H, Huang T, Jing J, Shen H, Cui W . Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009; 37(6):497-507. DOI: 10.1007/s15010-009-9034-2. View

Dallas J, Brown S, Hock K, Scott M, Skrupky L, Boyle 3rd W . Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting. Respir Care. 2011; 56(4):412-9. DOI: 10.4187/respcare.00979. View

Nyamande K, Lalloo U . Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis. 2006; 10(5):510-5. View

Schuetz P, Christ-Crain M, Muller B . Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype?. Swiss Med Wkly. 2009; 139(23-24):318-26. DOI: 10.4414/smw.2009.12584. View

10.

Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber P . Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174(1):84-93. DOI: 10.1164/rccm.200512-1922OC. View

11.

Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C . High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993; 341(8844):515-8. PMC: 7141580. DOI: 10.1016/0140-6736(93)90277-n. View

12.

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

13.

Gilbert D . Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011; 52 Suppl 4:S346-50. DOI: 10.1093/cid/cir050. View

14.

Saeed K, Dryden M, Bourne S, Paget C, Proud A . Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. J Hosp Infect. 2011; 78(4):289-92. DOI: 10.1016/j.jhin.2011.03.018. View

15.

Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M . Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004; 363(9409):600-7. DOI: 10.1016/S0140-6736(04)15591-8. View

16.

El-Solh A, Vora H, Knight 3rd P, Porhomayon J . Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med. 2011; 39(6):1251-6. PMC: 3102149. DOI: 10.1097/CCM.0b013e31820a942c. View

17.

Cuquemelle E, Soulis F, Villers D, Roche-Campo F, Ara Somohano C, Fartoukh M . Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med. 2011; 37(5):796-800. PMC: 7080069. DOI: 10.1007/s00134-011-2189-1. View

18.

Tokman S, Schuetz P, Bent S . Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations. Expert Rev Anti Infect Ther. 2011; 9(6):727-35. DOI: 10.1586/eri.11.45. View

19.

Huang D, Weissfeld L, Kellum J, Yealy D, Kong L, Martino M . Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008; 52(1):48-58.e2. PMC: 2775454. DOI: 10.1016/j.annemergmed.2008.01.003. View

20.

Kristoffersen K, Sogaard O, Wejse C, Black F, Greve T, Tarp B . Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clin Microbiol Infect. 2009; 15(5):481-7. DOI: 10.1111/j.1469-0691.2009.02709.x. View